A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ICU MEDICAL INC/DE
ICUI
$3.8B
Mkt Cap
$157.44
+2.59%
ICU MEDICAL INC/DE (ICUI) has a current P/E ratio of 5248.0, compared to its historical median P/E of 50.2. The stock is currently considered Expensive based on its historical valuation range.
ICU MEDICAL INC/DE (ICUI) has a 5-year average return on invested capital (ROIC) of 2.1%. This is below average and may indicate limited pricing power.
ICU MEDICAL INC/DE (ICUI) has a market capitalization of $3.9B. It is classified as a mid-cap stock.
ICU MEDICAL INC/DE (ICUI) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.22%.
Based on historical P/E analysis, ICU MEDICAL INC/DE (ICUI) appears expensive. The current P/E of 5248.0 is 10363% above its historical median of 50.2. The estimated fair value CAGR (P/E method) is -1.1%.
ICU MEDICAL INC/DE (ICUI) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
ICU MEDICAL INC/DE (ICUI) reported annual revenue of $2.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Risk Factors Summary Our business is subject to a number of risks and uncertainties, including those described in Part I, Item 1A. "Risk Factors" in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our securities. Principal risks and uncertainties include: •We derive a significant portion of our revenues from non-U.S. sales and from products manufactured at our non-U.S. facilities which are then imported to the U.S. We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade tensions. •If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.2B | 2.4B | 2.3B | 2.3B | 1.3B |
| Net Income | 46M | 732K | -118M | -30M | -74M | 103M |
| EPS | $1.86 | $0.03 | $-4.83 | $-1.23 | $-3.11 | $4.74 |
| Free Cash Flow | 83M | 92M | 125M | 82M | -152M | 199M |
| ROIC | 6.8% | 0.9% | 1.4% | 0.7% | -2.8% | 10.2% |
| Gross Margin | 37.9% | 36.8% | 34.6% | 32.8% | 30.6% | 37.3% |
| Debt/Equity | 0.61 | 0.61 | 0.81 | 0.84 | 0.79 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 44M | 43M | 43M | 23M | -43M | 123M |
| Operating Margin | 2.0% | 1.9% | 1.8% | 1.0% | -1.9% | 9.4% |
| ROE | 2.2% | 0.0% | -5.8% | -1.4% | -4.0% | 6.6% |
| Shares Outstanding | 25M | 24M | 24M | 24M | 24M | 22M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 309M | 342M | 379M | 1.3B | 1.4B | 1.3B | 1.3B | 1.3B | 2.3B | 2.3B | 2.4B | 2.2B | 2.2B |
| Gross Margin | 49.0% | 52.9% | 53.1% | 33.0% | 40.7% | 37.3% | 36.3% | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% | 37.9% |
| R&D | 18M | 16M | 13M | 51M | 53M | 49M | 43M | 47M | 93M | 85M | 89M | 87M | 85M |
| SG&A | 89M | 83M | 89M | 302M | 320M | 277M | 284M | 303M | 608M | 607M | 639M | 625M | 623M |
| EBIT | 39M | 69M | 83M | -13M | 30M | 107M | 98M | 123M | -43M | 23M | 43M | 43M | 44M |
| Op. Margin | 12.6% | 20.1% | 21.9% | -1.0% | 2.1% | 8.5% | 7.7% | 9.4% | -1.9% | 1.0% | 1.8% | 1.9% | 2.0% |
| Net Income | 26M | 45M | 63M | 69M | 29M | 101M | 87M | 103M | -74M | -30M | -118M | 732K | 46M |
| Net Margin | 8.5% | 13.2% | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% | 2.1% |
| Non-Recurring | 3.5M | 7.8M | 800K | 19M | -4.4M | -4.5M | 7.9M | 1.8M | 10M | 5.7M | 20M | 75M | 30M |
| Returns on Capital | |||||||||||||
| ROIC | 14.2% | 25.0% | 28.7% | 7.2% | 3.2% | 9.4% | 6.0% | 10.2% | -2.8% | 0.7% | 1.4% | 0.9% | 6.8% |
| ROE | 5.4% | 8.3% | 10.2% | 7.4% | 2.3% | 7.7% | 6.0% | 6.6% | -4.0% | -1.4% | -5.8% | 0.0% | 2.2% |
| ROA | 5.1% | 7.7% | 9.5% | 6.2% | 1.9% | 6.2% | 5.0% | 5.7% | -2.3% | -0.7% | -2.7% | 0.0% | 1.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 66M | 64M | 90M | 154M | 160M | 102M | 223M | 268M | -62M | 166M | 204M | 180M | 167M |
| Free Cash Flow | 50M | 51M | 67M | 80M | 67M | 4.6M | 131M | 199M | -152M | 82M | 125M | 92M | 83M |
| Owner Earnings | 37M | 33M | 56M | 69M | 61M | 3.1M | 113M | 150M | -333M | -103M | -62M | -77M | -91M |
| CapEx | 17M | 13M | 23M | 74M | 93M | 97M | 92M | 69M | 90M | 84M | 79M | 88M | 85M |
| Maint. CapEx | 19M | 18M | 19M | 67M | 75M | 77M | 86M | 90M | 235M | 229M | 220M | 201M | 201M |
| Growth CapEx | 0 | 0 | 4.3M | 7.9M | 18M | 20M | 6.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 19M | 18M | 19M | 67M | 75M | 77M | 86M | 90M | 235M | 229M | 220M | 201M | 201M |
| CapEx/OCF | 25.0% | 20.2% | 26.0% | 48.2% | 57.9% | 95.5% | 41.3% | 25.6% | N/A | 50.5% | 38.9% | 49.0% | 50.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 5.8M | 1.5M | 17M | 4.1M | 6.3M | 19M | 13M | 8.3M | 11M | 9.4M | 12M | 8.8M | 8.8M |
| Buyback Yield | 0.4% | 0.1% | 0.7% | 0.1% | 0.1% | 0.5% | 0.3% | 0.2% | 0.3% | 0.4% | 0.3% | 0.2% | 0.2% |
| Stock-Based Comp | 9.6M | 13M | 15M | 19M | 24M | 22M | 24M | 27M | 36M | 41M | 47M | 56M | 58M |
| Debt Repayment | 0 | 0 | 0 | 75M | 0 | 0 | 0 | 0 | 22M | 30M | 51M | 303M | 303M |
| Balance Sheet | |||||||||||||
| Net Debt | -347M | -376M | -444M | -243M | -360M | -258M | -212M | -1.1B | 1.2B | 1.3B | 967M | 978M | 993M |
| Cash & Equiv. | 276M | 336M | 445M | 290M | 345M | 269M | 396M | 553M | 209M | 254M | 309M | 308M | 288M |
| Long-Term Debt | 0 | 1.5M | 1.1M | 55M | 21M | 33M | 48M | 42M | 1.6B | 1.6B | 1.5B | 1.3B | 1.3B |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.05 | 0.02 | 0.02 | 0.13 | 0.03 | 0.79 | 0.84 | 0.81 | 0.61 | 0.61 |
| Interest Coverage | N/A | 1758.1 | 702.9 | -6.5 | 42.0 | 195.6 | 56.0 | 143.6 | -0.6 | 0.2 | 0.4 | 0.5 | 0.5 |
| Equity | 508M | 580M | 660M | 1.2B | 1.3B | 1.4B | 1.5B | 1.6B | 2.1B | 2.1B | 2.0B | 2.1B | 2.1B |
| Total Assets | 541M | 627M | 705M | 1.5B | 1.6B | 1.7B | 1.8B | 1.9B | 4.5B | 4.4B | 4.2B | 4.1B | 4.0B |
| Total Liabilities | 33M | 47M | 45M | 299M | 322M | 315M | 261M | 265M | 2.4B | 2.3B | 2.2B | 1.9B | -9.8M |
| Intangibles | 7.1M | 24M | 22M | 144M | 133M | 211M | 197M | 188M | 983M | 871M | 741M | 634M | 599M |
| Retained Earnings | 409M | 454M | 517M | 586M | 621M | 722M | 809M | 912M | 838M | 808M | 690M | 691M | 721M |
| Working Capital | 404M | 462M | 529M | 654M | 678M | 634M | 725M | 829M | 741M | 739M | 886M | 692M | 695M |
| Current Assets | 433M | 505M | 569M | 865M | 927M | 882M | 921M | 1.0B | 1.2B | 1.2B | 1.4B | 1.2B | 1.2B |
| Current Liabilities | 29M | 43M | 41M | 210M | 249M | 248M | 195M | 201M | 495M | 482M | 556M | 499M | 518M |
| Per Share Data | |||||||||||||
| EPS | 1.68 | 2.73 | 3.66 | 3.29 | 1.33 | 4.69 | 4.02 | 4.74 | -3.11 | -1.23 | -4.83 | 0.03 | 1.86 |
| Owner EPS | 2.38 | 2.02 | 3.23 | 3.28 | 2.83 | 0.14 | 5.24 | 6.92 | -13.95 | -4.28 | -2.56 | -3.14 | -3.66 |
| Book Value | 32.42 | 35.19 | 38.30 | 57.43 | 58.37 | 63.93 | 69.52 | 74.27 | 87.50 | 88.07 | 80.65 | 87.04 | 84.50 |
| Cash Flow/Share | 4.23 | 3.90 | 5.22 | 7.40 | 7.40 | 4.73 | 10.31 | 12.30 | -2.60 | 6.89 | 8.37 | 7.37 | 9.91 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 15.7M | 16.5M | 17.2M | 20.9M | 21.6M | 21.5M | 21.6M | 21.8M | 23.9M | 24.1M | 24.4M | 24.4M | 25.0M |
| Valuation | |||||||||||||
| P/E Ratio | 49.6 | 41.3 | 39.5 | 66.0 | 169.3 | 39.7 | 53.4 | 50.2 | N/A | N/A | N/A | N/A | 84.5 |
| P/FCF | 26.3 | 36.3 | 37.4 | 56.6 | 72.2 | 870.9 | 35.5 | 26.0 | N/A | 29.2 | 30.2 | 39.3 | 47.6 |
| EV/EBIT | 24.6 | 21.6 | 24.7 | N/A | 151.7 | 35.0 | 45.1 | 33.2 | N/A | 156.7 | 118.4 | 107.5 | 113.2 |
| Price/Book | 2.6 | 3.2 | 3.8 | 3.8 | 3.9 | 2.9 | 3.1 | 3.2 | 1.7 | 1.1 | 1.9 | 1.7 | 1.9 |
| Price/Sales | 3.3 | 4.8 | 5.3 | 2.8 | 4.1 | 3.6 | 3.3 | 3.6 | 1.9 | 1.6 | 1.3 | 1.5 | 1.8 |
| FCF Yield | 3.8% | 2.8% | 2.7% | 1.8% | 1.4% | 0.1% | 2.8% | 3.8% | -4.2% | 3.4% | 3.3% | 2.5% | 2.1% |
| Market Cap | 1.3B | 1.9B | 2.5B | 4.5B | 4.9B | 4.0B | 4.6B | 5.2B | 3.7B | 2.4B | 3.8B | 3.6B | 3.9B |
| Avg. Price | 64.48 | 99.40 | 116.04 | 170.46 | 261.95 | 210.57 | 193.02 | 214.84 | 184.57 | 150.68 | 130.61 | 137.65 | 157.44 |
| Year-End Price | 83.31 | 112.70 | 144.40 | 217.00 | 225.12 | 186.21 | 214.55 | 237.74 | 152.98 | 99.76 | 154.46 | 147.87 | 157.44 |
ICU MEDICAL INC/DE passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 41.8x vs a median of 36.4x. The company's 5-year average ROIC is 2.1% with a gross margin of 34.4%. Total shareholder yield (buybacks) is 0.2%. At current prices, the estimated annualized return to fair value is +6.6%.
ICU MEDICAL INC/DE (ICUI) has a net profit margin of 0.0%. This is a modest margin.
ICU MEDICAL INC/DE (ICUI) generated $92 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ICU MEDICAL INC/DE (ICUI) has a debt-to-equity ratio of 0.61. This indicates moderate leverage.
ICU MEDICAL INC/DE (ICUI) reported earnings per share (EPS) of $0.03 in its most recent fiscal year.
ICU MEDICAL INC/DE (ICUI) has a return on equity (ROE) of 0.0%. This indicates moderate shareholder returns.
ICU MEDICAL INC/DE (ICUI) has a 5-year average gross margin of 34.4%. This indicates decent pricing power.
The Ledger Terminal provides 19 years of financial data for ICU MEDICAL INC/DE (ICUI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ICU MEDICAL INC/DE (ICUI) has a book value per share of $87.04, based on its most recent annual SEC filing.
No recent press releases.